Venture Management Co Iii L... Net Worth

The estimated Net Worth of Venture Management Co Iii L... is at least $4.02 Milión dollars as of 25 June 2004. Venture L owns over 160,000 units of Momenta Pharmaceuticals stock worth over $4,022,487 and over the last 20 years Venture sold MNTA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture L MNTA stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Momenta Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Venture bought 160,000 units of MNTA stock worth $1,040,000 on 25 June 2004.

The largest trade Venture's ever made was buying 160,000 units of Momenta Pharmaceuticals stock on 25 June 2004 worth over $1,040,000. On average, Venture trades about 160,000 units every 0 days since 2004. As of 25 June 2004 Venture still owns at least 76,648 units of Momenta Pharmaceuticals stock.

You can see the complete history of Venture L stock trades at the bottom of the page.

Insiders trading at Momenta Pharmaceuticals

Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler a Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.

What does Momenta Pharmaceuticals do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Complete history of Venture L stock trades at Momenta Pharmaceuticals

Momenta Pharmaceuticals executives and stock owners

Momenta Pharmaceuticals executives and other stock owners filed with the SEC include:

• Donna Roy Grogan,
  Director
• Jose Carlos Gutierrez Ramos,
  Director
• Santiago Arroyo,
  SVP, Chief Medical Officer
• Craig A Wheeler,
  President & CEO
• Corey N. Fishman,
  Director
• Marsha Fanucci,
  Director
• James R Sulat,
  Director
• Bruce Leicher,
  SVP & General Counsel
• Matthew P. Ottmer,
  Chief Operating Officer
• Richard P Shea,
  VP, Chief Financial Officer
• Georges Gemayel,
  Director
• Thomas P Koestler,
  Director
• Steven C Gilman,
  Director
• Bruce Downey,
  Director
• Elizabeth Stoner,
  Director
• Scott M Storer,
  SVP, CFO
• James M. Roach,
  Senior VP, Development and Chi
• Michelle Robertson,
  Chief Financial Officer
• Anthony M. Manning,
  Chief Scientific Officer
• Jo Ann Beltramello,
  Chief HR and Inf. Officer
• Alejandra Carvajal,
  Chief Legal Officer
• Ian Fier,
  Chief Mfg and Program Officer
• Young Kwon,
  Chief Financial & Bus. Officer
• Peter Barrett,
  Director
• Peter Barton Hutt,
  Director
• Paul D Goldenheim,
  Director
• Stephen B Brugger,
  VP, Strategic Prod Devl.
• John L Zabriskie,
  Director
• Ram Sasisekharan,
  Director
• Venture Management Co Iii L...,
  
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Bennett M Shapiro,
  Director
• Stephen T Reeders,
  Director
• International Life Sciences...,
  10% owner
• Ganesh Venkataraman,
  VP, Technology
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Michael Franken,
  President, Biosimilars Busines
• Robert Langer,
  Director
• Carron Shmerling Lisa,
  V.P., Legal Affairs
• John E Bishop,
  VP Pharma Sciences & Manufact
• Susan K Whoriskey,
  VP, Licensing and Bus. Develop
• Alan L Crane,
  President and CEO
• Venture Fund V Lpatlas Vent...,
  
• John K Clarke,
  Director
• Jane F Barlow,
  Director
• Agnieszka Cieplinska,
  Chief Accounting Officer (PAO)